| Regulatory
Matters |
| |
Bevacizumab
|
| |
Calcium
gluconate injection |
| |
Daptomycin |
| |
Droperidol
Injection USP |
| |
Risk
of severe arrhythmia |
| |
Influenza
virus vaccine |
| |
Label
change due to risk of fever and febrile seizure |
| |
Lamotrigine |
| |
Methylnaltrexone
bromide |
| |
Midodrine
hydrochloride |
| |
Modafinil |
| |
Modified-release oral opioids |
| |
Octagam
(intravenous immunoglobulin) |
| |
Rosiglitazone |
| |
Saquinavir |
| |
Tigecycline |
| |
Topical
ketoprofen |
|
Safety of Medicines |
| |
Antidepressants |
| |
Carbidopa/levodopa
and entacapone |
| |
Dexrazoxane. |
| |
Estradiol
transdermal spray |
| |
H1N1
pandemic vaccines and antiviral |
| |
Inhaled
and intranasal corticosteroids |
| |
Isotretinoin |
| |
Lithium. |
| |
Monoclonal
antibodies |
| |
Nimodipine
oral capsules |
| |
Pioglitazone |
| |
Propolis |
| |
Tocilizumab
|
| Feature |
| |
Pharmacovigilance |
| |
Meeting
of the Global Advisory Committee on Vaccine Safety |
| |
Handling
of complaints of prequalified medicines |